In this interview, Prof Christophe Drouet (CNRS Senior Scientist) – an international specialist in bio-inspired apatites – relates the multifunctional potential of these intrinsically biocompatible compounds for a wealth of uses from bone tissue repair, to cell-scale medicine.
Here, we look into the many ways in which medical and safety technology manufacturer Dräger has been stepping up to help its customers through the COVID-19 crisis.
Andrea Ammon, Director at the European Centre for Disease Prevention and Control, takes us on a journey from COVID-19 to the future of public health surveillance.
Dr Ganesan Baranidharan, consultant in anaesthesia and pain medicine at the Leeds Teaching Hospitals NHS Trust, explains the power of neuromodulation for managing chronic pain and explains why comprehensive evidence is needed.
Leading pancreatic cancer experts Professor Matthias Löhr and Professor Monique van Leerdam of United European Gastroenterology’s (UEG) Public Affairs Committee discuss the importance of early diagnosis and the latest developments in treatment for pancreatic cancer.
New data from the Oxford COVID vaccine trial shows that the UK antidote is working well at Phase two, with defining percentages expected after Phase Three is complete.
Fintan Grant, NHS Digital’s Programme Head for Medicines and Pharmacy charts the recent change in the speed of healthcare delivery in light of COVID-19 including the importance of digital solutions.
Eight days after the Pfizer vaccine results (90% effective) brought collective hope to the world, the Moderna vaccine has proven to be 95% effective at fighting COVID-19.
Over 350 million people suffer from arthritis pain globally, which means significant levels of opiates are used to manage the condition - but what if there was a less addictive treatment?
Yesterday, at 6:45am in the US, the Pfizer vaccine was revealed to be over 90% effective - so when will the successful drug be available for the UK to use?
Researchers from the University of Liverpool and King’s College London have received a £2.3 million fund from UK Research and Innovation (UKRI) to investigate the neurological impacts of COVID-19.
